Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8054253 | 0.82 | CYP2D6 (0.46) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL7646012 | 0.82 | CA12 (0.45) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL915516 | 0.81 | L3MBTL1 (0.40) | CA12CA2CA9HTTLIPE | |
| SCHEMBL10509006 | 0.80 | KDM4E (0.48) | CYP2D6CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL6044868 | 0.80 | CA12 (0.44) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL9551386 | 0.79 | CA12 (0.47) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL14902206 | 0.79 | L3MBTL1 (0.42) | SMN1; SMN2HTTLIPE | |
| SCHEMBL3422335 | 0.79 | CA12 (0.50) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL19124539 | 0.78 | LIPE (0.58) | CYP2D6CA12CA1CA2CA9 | |
| SCHEMBL10667899 | 0.78 | CA12 (0.53) | CYP2D6CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| EP-2549991-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | Vifor (International) AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| CN-102892415-A | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR INT AG | 2013-01-23 | — | — | CN | disclosed |
| WO-2011117225-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117225-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| EP-0924247-B2 | Thermosetting resin composition and producing process thereof | NIPPON CATALYTIC CHEM IND (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-0924247-B1 | Thermosetting resin composition and producing process thereof | NIPPON CATALYTIC CHEM IND (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6140396-A | RESIN COMPOSITION INCLUDING N-OXYLS HAVING A SPECIFIC STRUCTURE AND A SYNTHETIC RESIN, SUCH AS A VINYL ESTER RESIN, AN URETHANE(METH)ACRYLATE RESIN, AN UNSATURATED POLYESTER RESIN, A POLYESTER(METH)ACRYLATE RESIN, AND ACRYLIC SYRUP | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0924247-A1 | Thermosetting resin composition and producing process thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-4179557-A | Acylation of 7-aminocephalosporanic acids | PRESIDENT OF OSAKA UNIVERSITY (JP) | 1979-12-18 | — | — | US | disclosed |
| US-4123611-A | N-protected amino compounds | PRESIDENT OF OSAKA UNIVERSITY (JP) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | CYP2D6 774/4885CA12 673/4885CA1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.